Physician profile
Deane Landon Smith
NPI 1255339180
$1,389.21
in general payments reported to CMS, 2019-2025
24 companies · $165 in 2025
The $165 reported for 2025 was less than what a typical Colon & Rectal Surgery provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $163 · 2020: $334 · 2021: $190 · 2022: $136 · 2023: $263 · 2024: $139 · 2025: $165.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $488 · Travel and Lodging: $79.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $488.00 |
| Travel and Lodging | $79.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $201.38 | 2020 | |
| Abbott Laboratories | $183.31 | 2023 | Thoratec Heartmate 3 Lvas Implant Kit |
| Medtronic, INC. | $139.93 | 2021-2025 | Interstim |
| Abiomed | $139.35 | 2024 | Impella |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $103.77 | 2019-2021 | |
| Palette Life Sciences, INC. | $80.94 | 2022 | |
| Axonics, INC. | $69.81 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $67.80 | 2020-2022 | |
| Ethicon US, LLC | $63.80 | 2019-2021 | |
| Tela Bio, INC. | $54.54 | 2019-2020 | |
| Medtronic USA, INC. | $44.98 | 2019-2020 | |
| Genmab U.S., INC. | $30.24 | 2025 | Epkinly |
| Integra Lifesciences Corporation | $25.00 | 2020 | |
| Rigel Pharmaceuticals, INC. | $23.54 | 2025 | Tavalisse, Rezlidhia, Gavreto |
| Covidien LP | $19.96 | 2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $19.45 | 2025 | Tecentriq |
| Beone Medicines USA, INC. | $18.47 | 2025 | Brukinsa |
| Kowa Pharmaceuticals America, INC. | $15.83 | 2023 | Seglentis |
| Merck Sharp & Dohme LLC | $15.21 | 2025 | Keytruda Qlex, Keytruda, Lynparza |
| Verastem, INC. | $15.18 | 2025 | Avmapki Fakzynja Co-Pack |
| Polynovo North America LLC | $14.90 | 2025 | Novosorb Btm |
| Shire North American Group INC | $14.72 | 2019 | |
| Novartis Pharmaceuticals Corporation | $14.71 | 2025 | |
| Stryker Corporation | $12.39 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deane Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.